Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Int J Urol. 2010 Jan;17(1):48-54. doi: 10.1111/j.1442-2042.2009.02405.x. Epub 2009 Dec 9.
To investigate post-transplant lymphoproliferative disorder (PTLD) following renal transplantation at our institution.
Medical records of 631 patients who underwent renal transplantation at Osaka University Hospital between March 1965 and December 2008 were reviewed.
PTLD following renal transplantation was detected in 10 patients (five men, five women; mean age at transplantation, 38.5 years). Mean duration from renal transplantation to the onset of PTLD was 7.1 years (range, 5 months to 18 years, 9 months). Mean duration of observation was 3.9 years from the onset of PTLD. Immunosuppressant therapy comprised multidrug combination therapy, including cyclosporine in six patients and tacrolimus in four patients. In addition to a reduction in the immunosuppressant dose, which was performed in all patients, PTLD was treated with surgery in seven patients, radiotherapy in two patients, rituximab in five patients, and cytotoxic chemotherapy in four patients. A complete remission in eight patients and progressive disease in two were observed. At last follow up, seven patients were alive and five patients had functioning grafts.
The incidence of PTLD following renal transplantation at our institution is 1.6% with onset occurring more than 5 years after transplantation in five patients. Consequently, with long-term renal graft survival now feasible, attention must be paid to detecting late-onset PTLD.
调查本机构肾移植后发生的移植后淋巴组织增生性疾病(PTLD)。
回顾了 1965 年 3 月至 2008 年 12 月期间在大阪大学医院接受肾移植的 631 例患者的病历。
在 10 例患者(5 例男性,5 例女性;移植时的平均年龄为 38.5 岁)中发现肾移植后发生了 PTLD。从肾移植到 PTLD 发病的平均时间为 7.1 年(范围,5 个月至 18 年 9 个月)。从 PTLD 发病到观察结束的平均时间为 3.9 年。免疫抑制剂治疗包括环孢素 6 例和他克莫司 4 例的多药联合治疗。除了所有患者均减少免疫抑制剂剂量外,7 例患者接受了手术治疗,2 例患者接受了放疗,5 例患者接受了利妥昔单抗治疗,4 例患者接受了细胞毒性化疗。观察到 8 例患者完全缓解和 2 例疾病进展。最后一次随访时,7 例患者存活,5 例患者移植肾功能正常。
本机构肾移植后发生 PTLD 的发生率为 1.6%,其中 5 例患者在移植后 5 年以上发病。因此,随着现在长期肾移植存活率成为可能,必须注意检测迟发性 PTLD。